Amneal Pharmaceuticals (AMRX) vs Cytokinetics (CYTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amneal Pharmaceuticals (AMRX) has outperformed Cytokinetics (CYTK) over the past year, gaining 76.7% versus a loss of 22.4%. Over five years, AMRX leads with a +396.9% price change compared with +30.1% for CYTK. Amneal Pharmaceuticals is the larger company by market cap ($7.36 billion vs $7.07 billion), about 1.0 times the size, while Cytokinetics is growing revenue faster (+376.6% vs +8.0%).
Amneal Pharmaceuticals converts more of its revenue into profit, with a net margin of 2.4% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | CYTK |
|---|---|---|
| Share price | $21.12 | $50.78 |
| Market cap | $7.36B | $7.07B |
| 1-day change | -1.26% | -1.32% |
| YTD return | +67.62% | -20.08% |
| 1-year return | +76.74% | -22.40% |
| 5-year return | +396.94% | +30.11% |
| P/E ratio (TTM) | 52.80 | — |
| Forward P/E | 17.13 | — |
| EPS (TTM) | $0.40 | $-6.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $88.04M |
| Revenue growth (YoY) | +8.05% | +376.56% |
| Net income (latest FY) | $72.06M | $-784.96M |
| Gross margin | 36.88% | — |
| Operating margin | 13.05% | -695.44% |
| Net margin | 2.39% | -891.60% |
| 52-week high | $22.13 | $88.31 |
| 52-week low | $11.71 | $50.32 |
| Distance from 52-week high | -4.54% | -42.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +15.01% | +115.48% |
| Average volume | 3.16M | 2.02M |
| Shares outstanding | 348.41M | 139.30M |
| Employees | 8,700 | 673 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRX has outperformed CYTK by 99.1 percentage points over the past year.
- Amneal Pharmaceuticals is more profitable, keeping 2.4 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +8.05%).
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
AMRX vs CYTK FAQ
Which is bigger, Amneal Pharmaceuticals or Cytokinetics?
Amneal Pharmaceuticals (AMRX) is larger, with a market capitalization of $7.36B compared with $7.07B for Cytokinetics (CYTK).
Which stock has performed better over the past year, AMRX or CYTK?
AMRX returned +76.74% over the past 12 months, compared with -22.40% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Amneal Pharmaceuticals and Cytokinetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.